GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (FRA:NB3) » Definitions » Cyclically Adjusted PB Ratio

Neurocrine Biosciences (FRA:NB3) Cyclically Adjusted PB Ratio : 13.75 (As of May. 24, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Cyclically Adjusted PB Ratio?

As of today (2024-05-24), Neurocrine Biosciences's current share price is €129.70. Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €9.43. Neurocrine Biosciences's Cyclically Adjusted PB Ratio for today is 13.75.

The historical rank and industry rank for Neurocrine Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:NB3' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.62   Med: 15.49   Max: 47.47
Current: 13.69

During the past years, Neurocrine Biosciences's highest Cyclically Adjusted PB Ratio was 47.47. The lowest was 1.62. And the median was 15.49.

FRA:NB3's Cyclically Adjusted PB Ratio is ranked worse than
96.22% of 687 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs FRA:NB3: 13.69

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Neurocrine Biosciences's adjusted book value per share data for the three months ended in Mar. 2024 was €21.826. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €9.43 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Neurocrine Biosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Neurocrine Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Cyclically Adjusted PB Ratio Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.88 22.21 14.36 15.67 13.72

Neurocrine Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.48 10.95 12.32 13.72 13.43

Competitive Comparison of Neurocrine Biosciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PB Ratio falls into.



Neurocrine Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Neurocrine Biosciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=129.70/9.43
=13.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Neurocrine Biosciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=21.826/131.7762*131.7762
=21.826

Current CPI (Mar. 2024) = 131.7762.

Neurocrine Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.296 100.560 3.009
201409 2.288 100.428 3.002
201412 2.213 99.070 2.944
201503 5.246 99.621 6.939
201506 4.852 100.684 6.350
201509 4.637 100.392 6.087
201512 4.517 99.792 5.965
201603 4.284 100.470 5.619
201606 3.909 101.688 5.066
201609 3.607 101.861 4.666
201612 3.436 101.863 4.445
201703 2.640 102.862 3.382
201706 3.483 103.349 4.441
201709 3.296 104.136 4.171
201712 3.541 104.011 4.486
201803 3.289 105.290 4.116
201806 3.574 106.317 4.430
201809 4.230 106.507 5.234
201812 4.654 105.998 5.786
201903 3.968 107.251 4.875
201906 4.677 108.070 5.703
201909 5.665 108.329 6.891
201912 6.212 108.420 7.550
202003 6.829 108.902 8.263
202006 7.920 108.767 9.595
202009 7.311 109.815 8.773
202012 9.901 109.897 11.872
202103 10.716 111.754 12.636
202106 11.223 114.631 12.902
202109 12.069 115.734 13.742
202112 12.813 117.630 14.354
202203 13.226 121.301 14.368
202206 14.085 125.017 14.847
202209 16.234 125.227 17.083
202212 16.706 125.222 17.580
202303 16.137 127.348 16.698
202306 17.524 128.729 17.939
202309 19.104 129.860 19.386
202312 20.737 129.419 21.115
202403 21.826 131.776 21.826

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Neurocrine Biosciences  (FRA:NB3) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Neurocrine Biosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (FRA:NB3) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (FRA:NB3) Headlines

No Headlines